


Androgen Receptor (AR) and Drug Resistance in Advanced Prostate Cancer



Androgen Deprivation Therapy (ADT)
Progression-free Survival < 2 years

ADT Resistance


Castration-resistant (CRPC)

Neuroendocrine (NEPC)

Chemotherapy
Increased Survival 2-4 months



R.I.P.

NEUROENDOCRINE TRANSDIFFERENTIATION



Enzalutamide
Increased Survival 2-8 months

Resistance mechanisms
AR mutations
AR-V truncated variants
AR by-pass



AR Mutational Burden - Adverse Drug Response Prediction

